Finance

Lists
TNGX:NASDAQ
Tango Therapeutics Inc
$24.00
+5.73%
(+1.30) 1D
$24.07
+0.27% (+0.065)
After hours
Closed: Sep 9, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNGX...
Open
$22.99
High
$25.52
Low
$22.63
Mkt. cap
4.05B
Avg. vol.
2.20M
Volume
0.00
52-wk high
$34.39
52-wk low
$6.25
EPS
-$0.84
Beta
1.12
Shares outstanding
168.61M
No. of employees
137
Open
$22.99
High
$25.52
Low
$22.63
Mkt. cap
4.05B
Avg. vol.
2.20M
Volume
0.00
52-wk high
$34.39
52-wk low
$6.25
EPS
-$0.84
Beta
1.12
Shares outstanding
168.61M
No. of employees
137
News stories
From web sources and news partners
About Tango Therapeutics Inc
CEO-
Employees137
Founded2017
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitetangotx.com
Analyst ratings
Based on 7 analysts giving stock ratings to TNGX in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for TNGX in the last 3 months.
Highest
Current $24.00
$68.00 (+183.33%)
Average
$47.71 (+98.79%)
Lowest
$35.00 (+45.83%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
$68.00
+183.3%
08/18/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
$40.00
+66.7%
08/17/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$39.00
+62.5%
08/12/2026
Michael Schmidt
Guggenheim
Buy
Reiterated
$35.00
+45.8%
08/11/2026
John Newman
Canaccord Genuity
Buy
Maintained
$46.00
+91.7%
08/12/2026
Joseph Catanzaro
Mizuho Securities
Buy
Maintained
$40.00
+66.7%
07/17/2026
Brian Cheng
J.P. Morgan
Buy
Initiated
$46.00
+91.7%
07/15/2026
Maury Raycroft
Jefferies
Buy
Upgraded
$60.00
+150%
06/26/2026
Kalpit Patel
Wolfe Research
Buy
Upgraded
$35.00
+45.8%
06/08/2026
Yuan Zhi
B. Riley Securities
Buy
Reiterated
$35.00
+45.8%
06/09/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$32.00
+33.3%
06/01/2026
Kelsey Goodwin
Piper Sandler
Hold
Downgraded
$24.00
0%
05/15/2026
Andrew Berens
Leerink Partners
Buy
Reiterated
$55.00
+129.2%
05/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
53.81M
-
-
-
Cost of goods sold
30.82M
32.10M
33.53M
37.20M
Cost of revenue
30.82M
32.10M
33.53M
37.20M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.92M
9.76M
15.24M
22.59M
Operating expense
8.92M
9.76M
15.24M
22.59M
Total operating expenses
39.74M
41.86M
48.77M
59.78M
Operating income
14.07M
-41.86M
-48.77M
-59.78M
Other non operating income
705.00K
3.30M
-45.00K
722.00K
EBT including unusual items
15.87M
-38.80M
-45.51M
-55.34M
EBT excluding unusual items
15.87M
-36.88M
-46.64M
-55.34M
Income tax expense
-10.00K
-55.00K
1.00K
1.00K
Effective tax rate
-0.06%
0.14%
-
-
Other operating expenses
-
-
-
-
Net income
15.88M
-38.75M
-45.51M
-55.34M
Net profit margin
29.52%
-
-
-
Earnings per share
0.13
-0.29
-0.32
-0.37
Interest and investment income
1.10M
1.68M
2.18M
3.72M
Interest expense
-
-
-
-
Net interest expenses
1.10M
1.68M
2.18M
3.72M
Depreciation and amortization charges
-
-
-
-
EBITDA
14.63M
-41.38M
-48.31M
-59.36M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps